https://orcid.org/0000-0002-4379-5283
Figures & data
Table 1. Monoclonal antibodies authorized in the EU (by October 2020) and included in the PDL in Bulgaria.
Figure 1. Comparison of the authorized mAbs in the EU and the reimbursed ones in Bulgaria by brand name and INN.
Table 2. Reimbursed costs for mAbs included in PDL, Annex 1 for the period 2016–2020.
Figure 2. Costs for the most cost-consuming mAbs included in PDL, Annex 1.
Figure 3. Number of health-insured ambulatory patients treated with the most cost-consuming mAbs.
Figure 4. Reference prices dynamic for adalimumab and pembrolizumab (in euro).
Figure 5. Reimbursed costs for the original product and biosimilars with INN Adalimumab for the period of 2019–2020.
Figure 6. Reimbursed costs and number of patients treated with Adalimumab by disease (2016–2022).
Figure 7. Actual and expected costs for adalimumab by disease (2016–2022).
Figure 8. Share of the costs for mAbs from group B with the most significant dynamics.
Table 3. mAbs costs from group B*.
Figure 9. Trends in the mAbs reimbursed market.
Data availability statement
Data sharing not applicable.